Immutep Completes Recruitment for Part A of TACTI-002 trial
Filed with ASX · · 3 pages · English
Story so far
Earlier from Immutep
- Immutep receives A$1,437,826 R&D Tax Incentive
- Immutep announces improving data from TACTI-002 ph II trial
- Immutep receives $3.6M R&D French tax incentive
- Immutep granted Japanese patent for eftilagimod alpha
- INSIGHT-004 and TACTI-002 data to be presented at ASCO
Later from Immutep
- US patent granted for IMP701 antibody
- Immutep granted US patent for eftilagimod alpha
- Recruitment of stage 1 of part B in TACTI-002 study complete
- Appendix 4E & 2020 Full Year Statutory Accounts
- IMM & Monash Uni receive funding grant for LAG-3 Research
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep